Fosun Pharma and AriBio Forge Global Alliance for Alzheimer's Treatment
Fosun Pharma and AriBio Join Forces for Alzheimer's Breakthrough
On May 13, 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, and AriBio Co., Ltd., a biopharmaceutical innovator focused on neurodegenerative diseases, revealed the signing of a significant global option agreement for AR1001. This new drug candidate has the potential to revolutionize treatment for Alzheimer's disease (AD).
Exclusive Agreement Details
The structure of the agreement operates on an
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.